Upon joining the study, you will be randomly assigned to one of two treatment groups. This process is called randomization and ensures fairness in the study.

You will receive either izalontamab brengitecan (also called BL-B01D1 or BMS-986507) or a platinum-based chemotherapy combination. The platinum-based chemotherapy consists of either cisplatin or carboplatin combined with pemetrexed.

The study is open-label, which means you and your doctor will know which treatment you are receiving.

If you join during the first phase of the study (Phase 2), the main goal is to determine the recommended dose of izalontamab brengitecan for the next phase.

You will receive your assigned treatment through an intravenous infusion, which means the medication will be given directly into your vein.

If you are assigned to the platinum-based chemotherapy group, carboplatin or cisplatin will be given through an intravenous infusion, and pemetrexed will also be given through an intravenous infusion.

Additionally, you may receive pegfilgrastim as a subcutaneous injection, which means it will be injected under your skin.

Your treatment will continue in cycles, and your doctor will monitor your response to the medication and any side effects you experience.

If you join during the second phase of the study (Phase 3), the main goal is to compare how well izalontamab brengitecan works compared to platinum-based chemotherapy in delaying disease progression.

You will receive your assigned treatment in the same manner as described in Phase 2.

Izalontamab brengitecan will be given through an intravenous infusion.

If you are assigned to the chemotherapy group, you will receive either carboplatin or cisplatin combined with pemetrexed, all given through intravenous infusions.

Pegfilgrastim may be given as a subcutaneous injection to help support your immune system during treatment.

Your treatment will continue in cycles until your disease progresses, you experience unacceptable side effects, or you and your doctor decide to stop treatment.

Throughout the study, you will have regular appointments to monitor your health and how the treatment is affecting your cancer.

Your doctor will perform imaging scans to check the size and status of your tumor. These assessments will follow a standard method called RECIST v1.1, which is a set of rules used to measure how tumors respond to treatment.

The scans will be reviewed by independent experts who do not know which treatment you are receiving. This is called Blinded Independent Central Review.

Your doctor will also monitor you for any side effects or unwanted reactions to the medication.

Blood tests and other examinations may be performed to assess how your body is responding to the treatment.

You will continue receiving your assigned treatment as long as it is working to control your cancer and you are tolerating it well.

Your doctor will regularly evaluate whether the treatment should continue based on your scan results and overall health.

If your cancer progresses or you experience side effects that are too difficult to manage, your treatment may be stopped or adjusted.

Once your treatment ends, you will enter a follow-up period.

During this time, your doctor will continue to monitor your health and cancer status.

The purpose of the follow-up is to collect information about your overall survival, which means how long you live after starting the treatment, and to track any long-term effects of the treatment.

Follow-up appointments may include physical examinations, imaging scans, and questionnaires about your well-being.